Key Insights

Highlights

Success Rate

93% trial completion (above average)

Published Results

352 trials with published results (14%)

Research Maturity

1520 completed trials (61% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.4%

111 terminated out of 2497 trials

Success Rate

93.2%

+6.7% vs benchmark

Late-Stage Pipeline

20%

509 trials in Phase 3/4

Results Transparency

23%

352 of 1520 completed with results

Key Signals

352 with results93% success111 terminated

Data Visualizations

Phase Distribution

2,093Total
Not Applicable (1160)
Early P 1 (17)
P 1 (212)
P 2 (195)
P 3 (237)
P 4 (272)

Trial Status

Completed1,520
Unknown317
Recruiting269
Terminated111
Not Yet Recruiting103
Active Not Recruiting90

Trial Success Rate

93.2%

Benchmark: 86.5%

Based on 1520 completed trials

Clinical Trials (2497)

Showing 20 of 20 trials
NCT07646067Not ApplicableNot Yet Recruiting

Closed Loop Glucose Control in a Simulated ICU Setting

NCT07641309RecruitingPrimary

Measurements Before and After Participation in a Health Intervention Programme in Halsnaes Municipality

NCT06902857Active Not RecruitingPrimary

Study on the Predictive Value of High-sensitivity Cardiac Troponin I, N-terminal Pro-B-natriuretic Peptide, and Soluble Suppression of Tumorigenesis-2 for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV)

NCT07642518Not ApplicableNot Yet RecruitingPrimary

Transcutaneous Auricular Vagus Nerve Stimulation in Type 2 Diabetes With Mild Cognitive Impairment

NCT07011147Not ApplicableRecruiting

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

NCT04282395Not ApplicableActive Not RecruitingPrimary

Resilience-Based Diabetes Self-Management Education (RB-DSME) for African Americans

NCT06184568Phase 3CompletedPrimary

A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

NCT07032844Not ApplicableNot Yet RecruitingPrimary

Advancing Diabetes Management for People With Physical Disabilities Optimally Through Primary Care-Based Telehealth (ADDOPT)

NCT06291155Phase 4RecruitingPrimary

Mechanism of SGLT2 Inhibition in the Kidney

NCT07641361Not ApplicableRecruiting

Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy

NCT07417631Active Not RecruitingPrimary

Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.

NCT07636161Phase 4Not Yet RecruitingPrimary

PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon)

NCT07622628Not ApplicableRecruitingPrimary

AIM-MET: AI-Guided Microbiome-Targeted Nutrition for Glycemic Improvement in Type 2 Diabetes

NCT05648383Not ApplicableCompletedPrimary

Promote Health With Digital Tools Among Adults With Type 2 Diabetes/Prediabetes and/or Hypertension

NCT07633171Not Yet RecruitingPrimary

Multimodal Glucose Prediction in Type 2 Diabetes

NCT07560813Not ApplicableActive Not RecruitingPrimary

NOURISH - A Healthcare-community Partnership to Improve Nutrition for Optimal Glycemic Control and Pregnancy Outcomes With Pregestational Diabetes

NCT04965935Phase 3Completed

Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients

NCT06269107Phase 3CompletedPrimary

A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

NCT06740435Not ApplicableActive Not RecruitingPrimary

Enhancing Telemedicine for T2D

NCT06715514Not ApplicableRecruiting

Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes

Scroll to load more

Research Network

Activity Timeline